GlassScriptPhysician profile
Sijo Devasia
NPI 1366046492
$1,287.45
in general payments reported to CMS, 2019-2025
34 companies · $89.53 in 2025
The $89.53 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.59 · 2023: $1,079 · 2024: $24.52 · 2025: $89.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $924 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.92 |
| Education | $268.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $147.13 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $143.44 | 2023 | Monoferric |
| Incyte Corporation | $115.95 | 2023 | Jakafi |
| Aveo Pharmaceuticals, INC. | $114.94 | 2023 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $64.74 | 2023 | Eliquis |
| Bioventus LLC | $51.02 | 2022-2024 | Durolane |
| Amgen INC. | $47.25 | 2023 | Vectibix, Xgeva, Nplate |
| Daiichi Sankyo INC. | $44.26 | 2023 | Enhertu |
| Novartis Pharmaceuticals Corporation | $41.48 | 2023 | |
| Merck Sharp & Dohme LLC | $36.03 | 2023 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $35.14 | 2023 | Ninlaro, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $32.44 | 2023 | Libtayo |
| Janssen Biotech, INC. | $32.31 | 2023 | Darzalex, Tecvayli |
| Seagen INC. | $27.12 | 2023 | Adcetris |
| Glaxosmithkline, LLC. | $26.17 | 2022-2023 | Ojjaara |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $25.21 | 2025 | Cologuard Collection Kit |
| Celgene Corporation | $24.01 | 2023 | Reblozyl |
| Stemline Therapeutics INC. | $22.21 | 2023 | Orserdu |
| Emmaus Medical, INC. | $20.39 | 2023 | Endari |
| Genzyme Corporation | $19.63 | 2023 | |
| Astellas Pharma US INC | $18.67 | 2023 | Xospata |
| Genmab U.S., INC. | $16.98 | 2023 | Tivdak |
| Beigene USA, INC. | $16.68 | 2023 | Brukinsa |
| Pfizer INC. | $16.49 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.42 | 2023 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $16.12 | 2023 | Tavalisse, Rezlidhia |
| Janssen Pharmaceuticals, INC | $15.73 | 2023 | Xarelto |
| Sumitomo Pharma America, INC. | $15.54 | 2023 | Orgovyx |
| Genentech USA, INC. | $15.00 | 2022 | |
| Lilly USA, LLC | $14.53 | 2022 | |
| Immunogen, INC. | $14.44 | 2023 | Elahere |
| Pharmaessentia USA Corporation | $13.96 | 2023 | Besremi |
| Baxter Healthcare | $13.23 | 2022 | |
| Novo Nordisk INC | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sijo Devasia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.